Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 adaptive study of PF-06730512 in focal segmental glomerulosclerosis
2019-003607-35Phase 2Completed
- Sponsor
- Pfizer
- Start
- Oct 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of PF-06730512 in focal segmental glomerulosclerosis (FSGS), sponsored by Pfizer. Primary endpoint: Percentage change from baseline to Week 13 in Urinary Protein to Creatinine Ratio (UPCR). Started Oct 2020; status: completed.
02
Drugs
PF-06730512
03
Conditions
focal segmental glomerulosclerosis (FSGS)
Beyond the preview
Go deeper on 2019-003607-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-003607-35.